Roland Diggelmann Net Worth

The estimated Net Worth of Roland D Diggelmann is at least $376 millier dollars as of 13 November 2023. Mr. Diggelmann owns over 315 units of Accelerate Diagnostics Inc stock worth over $652 and over the last 5 years he sold AXDX stock worth over $0. In addition, he makes $375,805 as Independent Director at Accelerate Diagnostics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Diggelmann AXDX stock SEC Form 4 insiders trading

Roland has made over 1 trades of the Accelerate Diagnostics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he bought 315 units of AXDX stock worth $323,360 on 13 November 2023.

The largest trade he's ever made was buying 315 units of Accelerate Diagnostics Inc stock on 13 November 2023 worth over $323,360. On average, Roland trades about 63 units every 0 days since 2019. As of 13 November 2023 he still owns at least 405 units of Accelerate Diagnostics Inc stock.

You can see the complete history of Mr. Diggelmann stock trades at the bottom of the page.

Roland Diggelmann biography

Roland D. Diggelmann serves as Independent Director of the Company. Mr. Diggelmann has served as the Chief Executive Officer for Smith-Nephew, a global medical technology company, since 2019 and as a director since 2018. Prior to joining Smith-Nephew, Mr. Diggelmann held executive positions at Roche Diagnostics from 2008 to 2018, including serving as Chief Executive Officer of the Diagnostics Division of F. Hoffman-La Roche Ltd from 2012 until 2018. Mr. Diggelmann has also held executive positions in EMEA and Asia Pacific at Zimmer Group and Sulzer Medica AG (later known as Centerpulse). Mr. Diggelmann serves as a director of Igenomix and Heartforce AG. Mr. Diggelmann studied Business Administration at the University of Berne.

What is the salary of Roland Diggelmann?

As the Independent Director of Accelerate Diagnostics Inc, the total compensation of Roland Diggelmann at Accelerate Diagnostics Inc is $375,805. There are 4 executives at Accelerate Diagnostics Inc getting paid more, with John Phillips having the highest compensation of $12,300,900.

How old is Roland Diggelmann?

Roland Diggelmann is 53, he's been the Independent Director of Accelerate Diagnostics Inc since 2019. There are 11 older and 3 younger executives at Accelerate Diagnostics Inc. The oldest executive at Accelerate Diagnostics Inc is Jack Schuler, 79, who is the Independent Director.

What's Roland Diggelmann's mailing address?

Roland's mailing address filed with the SEC is IM LANGACHER 44, , GREIFENSEE, V8, 8606.

Insiders trading at Accelerate Diagnostics Inc

Over the last 12 years, insiders at Accelerate Diagnostics Inc have traded over $26,833,308 worth of Accelerate Diagnostics Inc stock and bought 16,366,880 units worth $209,384,489 . The most active insiders traders include Jack W Schuler, Larry N Feinberg et Matthew Strobeck. On average, Accelerate Diagnostics Inc executives and independent directors trade stock every 16 days with the average trade being worth of $132,645. The most recent stock trade was executed by Hany Massarany on 28 June 2024, trading 4,737 units of AXDX stock currently worth $7,627.

What does Accelerate Diagnostics Inc do?

accelerate diagnostics, inc. (nasdaq:axdx), is an in vitro diagnostics company focused on developing and commercializing innovative systems for the rapid identification and antimicrobial susceptibility testing of infectious pathogens. the company's revolutionary id/ast platform utilizes a proprietary process with both genomic and phenotypic detection technologies that significantly decreases time to result while achieving high sensitivity and specificity. in addition to the id/ast development pipeline, the company also owns and licenses its proprietary optichem™ surface coatings technology, which has numerous applications for binding in bio-analytical systems, such as microarrays.

Complete history of Mr. Diggelmann stock trades at Accelerate Diagnostics Inc et Mettler-Toledo International

Accelerate Diagnostics Inc executives and stock owners

Accelerate Diagnostics Inc executives and other stock owners filed with the SEC include:

• John Phillips,
  Chief Executive Officer, Chief Operating Officer, Director
• Steve Reichling,
  Chief Financial Officer
• Jack Phillips,
  CEO, Pres & Director
• Ron Price,
  Senior Vice President, Head of Commercial Operations, Americas
• Roland Diggelmann,
  Independent Director
• Louise Francesconi,
  Independent Director
• Steve Reichling,
  CFO & Chief Accounting Officer
• Ron Price,
  Chief Commercial Officer of Americas
• Charles Watts,
  Independent Director
• Frank ten Brink,
  Independent Director
• Matthew Strobeck,
  Independent Director
• Jack Schuler,
  Independent Director
• Mark Miller,
  Independent Director
• Thomas Brown,
  Independent Director
• John Patience,
  Independent Chairman of the Board
• Nedal Safwat,
  Chief Strategy Officer
• Dr. Lawrence Mertz,
  Sr. VP and Head of R&D
• John Meduri,
  Chief Strategy Officer
• Laura Costa,
  Sr. VP & Head of Global Customer Support
• Cherif Bousselham,
  Sr. VP & Head of Sales - EMEA
• Gretchen Strohminger,
  Sr. VP and Head of HR & Culture
• Michael Bridge,
  Sr. VP, Gen. Counsel & Sec.
• Laura Pierson,
  Investor Relations Officer
• Larry N Feinberg,
  10% owner
• Pete Bantock,
  CHIEF COMMERCIAL OFFICER
• Lawrence Mehren,
  PRESIDENT AND CEO
• Marran H. Ogilvie,
  Director
• Jennifer Regan,
  Director
• Mark S. Black,
  Director
• Ventures, Llc Abeja,
  10% owner
• Romney Humphries,
  Chief Scientific Officer
• Larry Michael Mertz,
  Chief Technology Officer
• Hany Massarany,
  Director
• Jack Phillips,
  Chief Executive Officer
• Wayne Burris,
  Director
• David Patience,
  Chief Financial Officer